207940.KO Samsung Biologics Co Ltd

Healthcare Biotechnology Korea Stock Exchange
1,520,000 KRW
Close of Nov 5, 2026
1,150,000 1,973,602
Market cap
KRW 70.8T
P/E
37.6x
P/B
8.08x
ROE
21.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 207940.KO undervalued?

Graham number

The Graham number of Samsung Biologics Co Ltd cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Samsung Biologics Co Ltd fundamental analysis

No fundamental analysis for Samsung Biologics Co Ltd yet.

Samsung Biologics Co Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Samsung Biologics Co Ltd

Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, …

Full company profile